245 related articles for article (PubMed ID: 32014999)
1. A comparative study of small molecules targeting eIF4A.
Naineni SK; Itoua Maïga R; Cencic R; Putnam AA; Amador LA; Rodriguez AD; Jankowsky E; Pelletier J
RNA; 2020 May; 26(5):541-549. PubMed ID: 32014999
[TBL] [Abstract][Full Text] [Related]
2. Selective targeting of the DEAD-box RNA helicase eukaryotic initiation factor (eIF) 4A by natural products.
Shen L; Pelletier J
Nat Prod Rep; 2020 May; 37(5):609-616. PubMed ID: 31782447
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of translation initiation as cancer therapeutics.
Lindqvist L; Pelletier J
Future Med Chem; 2009 Dec; 1(9):1709-22. PubMed ID: 21425987
[TBL] [Abstract][Full Text] [Related]
4. Investigation of the mechanism of action of a potent pateamine A analog, des-methyl, des-amino pateamine A (DMDAPatA).
Kommaraju SS; Aulicino J; Gobbooru S; Li J; Zhu M; Romo D; Low WK
Biochem Cell Biol; 2020 Aug; 98(4):502-510. PubMed ID: 32008367
[TBL] [Abstract][Full Text] [Related]
5. Amidino-Rocaglates: A Potent Class of eIF4A Inhibitors.
Chu J; Zhang W; Cencic R; Devine WG; Beglov D; Henkel T; Brown LE; Vajda S; Porco JA; Pelletier J
Cell Chem Biol; 2019 Nov; 26(11):1586-1593.e3. PubMed ID: 31519508
[TBL] [Abstract][Full Text] [Related]
6. Functional mimicry revealed by the crystal structure of an eIF4A:RNA complex bound to the interfacial inhibitor, desmethyl pateamine A.
Naineni SK; Liang J; Hull K; Cencic R; Zhu M; Northcote P; Teesdale-Spittle P; Romo D; Nagar B; Pelletier J
Cell Chem Biol; 2021 Jun; 28(6):825-834.e6. PubMed ID: 33412110
[TBL] [Abstract][Full Text] [Related]
7. Stimulation of mammalian translation initiation factor eIF4A activity by a small molecule inhibitor of eukaryotic translation.
Bordeleau ME; Matthews J; Wojnar JM; Lindqvist L; Novac O; Jankowsky E; Sonenberg N; Northcote P; Teesdale-Spittle P; Pelletier J
Proc Natl Acad Sci U S A; 2005 Jul; 102(30):10460-5. PubMed ID: 16030146
[TBL] [Abstract][Full Text] [Related]
8. Stopping trouble before it starts.
Clardy J
ACS Chem Biol; 2006 Feb; 1(1):17-9. PubMed ID: 17163634
[TBL] [Abstract][Full Text] [Related]
9. Substrate-dependent targeting of eukaryotic translation initiation factor 4A by pateamine A: negation of domain-linker regulation of activity.
Low WK; Dang Y; Bhat S; Romo D; Liu JO
Chem Biol; 2007 Jun; 14(6):715-27. PubMed ID: 17584618
[TBL] [Abstract][Full Text] [Related]
10. RNA-mediated sequestration of the RNA helicase eIF4A by Pateamine A inhibits translation initiation.
Bordeleau ME; Cencic R; Lindqvist L; Oberer M; Northcote P; Wagner G; Pelletier J
Chem Biol; 2006 Dec; 13(12):1287-95. PubMed ID: 17185224
[TBL] [Abstract][Full Text] [Related]
11. A novel Bcr-Abl-mTOR-eIF4A axis regulates IRES-mediated translation of LEF-1.
Tsai BP; Jimenez J; Lim S; Fitzgerald KD; Zhang M; Chuah CT; Axelrod H; Wilson L; Ong ST; Semler BL; Waterman ML
Open Biol; 2014 Nov; 4(11):140180. PubMed ID: 25392452
[TBL] [Abstract][Full Text] [Related]
12. CRISPR-Mediated Drug-Target Validation Reveals Selective Pharmacological Inhibition of the RNA Helicase, eIF4A.
Chu J; Galicia-Vázquez G; Cencic R; Mills JR; Katigbak A; Porco JA; Pelletier J
Cell Rep; 2016 Jun; 15(11):2340-7. PubMed ID: 27239032
[TBL] [Abstract][Full Text] [Related]
13. Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma.
Demosthenous C; Han JJ; Stenson MJ; Maurer MJ; Wellik LE; Link B; Hege K; Dogan A; Sotomayor E; Witzig T; Gupta M
Oncotarget; 2015 Apr; 6(11):9488-501. PubMed ID: 25839159
[TBL] [Abstract][Full Text] [Related]
14. Targeting the eIF4A RNA helicase blocks translation of the MUC1-C oncoprotein.
Jin C; Rajabi H; Rodrigo CM; Porco JA; Kufe D
Oncogene; 2013 Apr; 32(17):2179-88. PubMed ID: 22689062
[TBL] [Abstract][Full Text] [Related]
15. Targeting the eIF4A RNA helicase as an anti-neoplastic approach.
Chu J; Pelletier J
Biochim Biophys Acta; 2015 Jul; 1849(7):781-91. PubMed ID: 25234619
[TBL] [Abstract][Full Text] [Related]
16. Translational dysregulation by Pateamine A.
Korneeva NL
Chem Biol; 2007 Jan; 14(1):5-7. PubMed ID: 17254945
[TBL] [Abstract][Full Text] [Related]
17. Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4A.
Thompson PA; Eam B; Young NP; Fish S; Chen J; Barrera M; Howard H; Sung E; Parra A; Staunton J; Chiang GG; Gerson-Gurwitz A; Wegerski CJ; Nevarez A; Clarine J; Sperry S; Xiang A; Nilewski C; Packard GK; Michels T; Tran C; Sprengeler PA; Ernst JT; Reich SH; Webster KR
Mol Cancer Ther; 2021 Jan; 20(1):26-36. PubMed ID: 33037136
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of eukaryotic translation initiation by the marine natural product pateamine A.
Low WK; Dang Y; Schneider-Poetsch T; Shi Z; Choi NS; Merrick WC; Romo D; Liu JO
Mol Cell; 2005 Dec; 20(5):709-22. PubMed ID: 16337595
[TBL] [Abstract][Full Text] [Related]
19. Transcriptome-wide characterization of the eIF4A signature highlights plasticity in translation regulation.
Rubio CA; Weisburd B; Holderfield M; Arias C; Fang E; DeRisi JL; Fanidi A
Genome Biol; 2014; 15(10):476. PubMed ID: 25273840
[TBL] [Abstract][Full Text] [Related]
20. Rocaglates Induce Gain-of-Function Alterations to eIF4A and eIF4F.
Chu J; Zhang W; Cencic R; O'Connor PBF; Robert F; Devine WG; Selznick A; Henkel T; Merrick WC; Brown LE; Baranov PV; Porco JA; Pelletier J
Cell Rep; 2020 Feb; 30(8):2481-2488.e5. PubMed ID: 32101697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
